ExoCoBio Inc. raises $26.7M in Series B Funding

관리자
11 Jan 2019
Views 9904

5c37f7465247b.jpg


 ExoCoBio Inc. announced that it recently raised about $27 million in its series B funding. Top tier Korean investors participated in this round, including Seven Tree Equity Partners, CSQUARED Global Asset Management, TS Investment Partners, K2 Investment, Intervest, KDB Capital, Atinum Investment, GU Equity Partners, QUANTUM Ventures Korea, Platinum technology Investment.

Since it was established in January 2017, ExoCoBio has raised about $46 million accumulatively including series A round in April 2017 of $11 million.

Series B money will be used to set up GMP-compliant exosome manufacturing facilities to produce exosome pharmaceuticals, to attract thigh quality talents, and to secure additional business opportunities for commercialization in cosmetics industry.

“We are very delighted by the level of enthusiasm and financial support from our investors” said Byong Cho, CEO of ExoCoBio. “And we are going to step up our R&D and business so that ExoCoBio will be one of leaders in the global exosome industry.”

Recently, ExoCoBio published a scientific paper on that stem cell-derived exosomes dramatically can improve atopic dermatitis and inhibit a variety of inflammatory targets in the journal of Stem Cell Research and Therapy, which is the world’s first

In cosmeceutical business, ExoCoBio has been launching its own exosome-based brands and products, such as EXOMAGETM, CelltweetTM and ASCE+TM.
<!--[if !supportLineBreakNewLine]-->

0 165